Reports

Drug name	NICE TAs	Comments
Temsirolimus infusion (Torisel®)	TA207 - Temsirolimus for the treatment of relapsed or refractory mantle cell lymphoma (terminated appraisal) (Negative TA) TA178 - Bevacizumab (first-line), sorafenib (first- and second-line), sunitinib (second-line) and temsirolimus (first-line) for the treatment of advanced and/or metastatic renal cell carcinoma (Negative TA)	Hospital use only
Tenecteplase injection	TA52 - Guidance on the use of drugs for early thrombolysis in the treatment of acute myocardial infarction	Hospital use only
Teriflunomide	TA303 - Teriflunomide for treating relapsing–remitting multiple sclerosis
Teriparatide injection	TA161 - Raloxifene and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women
Tezepelumab	TA880 - Tezepelumab for treating severe asthma
Thalidomide capsules	TA228 - Bortezomib and thalidomide for the first-line treatment of multiple myeloma
Ticagrelor tablets	TA236 - Ticagrelor for the treatment of acute coronary syndromes
Tildrakizumab	TA575 - Tildrakizumab for treating moderate to severe plaque psoriasis
Timodine cream	TA81 - Frequency of application of topical corticosteroids for atopic eczema	Mild steroid potency
Tirzepatide (Mounjaro®)	TA924: Tirzepatide for treating type 2 diabetes

University Hospitals Birmingham NHS Foundation Trust